Associations - CD19 inhibitor

No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
CD19 positive	Acute Lymphocytic Leukemia	CD19 positive	Acute Lymphocytic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lenalidomide + tafasitamab-cxix Sensitive: A1 - Approval lenalidomide + tafasitamab-cxix Sensitive : A1	lenalidomide + tafasitamab-cxix Sensitive: A1 - Approval lenalidomide + tafasitamab-cxix Sensitive : A1
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A2 - Guideline blinatumomab Sensitive : A2	blinatumomab Sensitive: A2 - Guideline blinatumomab Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2
CD20 positive	B Acute Lymphoblastic Leukemia	CD20 positive	B Acute Lymphoblastic Leukemia	rituximab + blinatumomab Sensitive: A2 - Guideline rituximab + blinatumomab Sensitive : A2	rituximab + blinatumomab Sensitive: A2 - Guideline rituximab + blinatumomab Sensitive : A2
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	blinatumomab Sensitive: C2 – Inclusion Criteria blinatumomab Sensitive : C2	blinatumomab Sensitive: C2 – Inclusion Criteria blinatumomab Sensitive : C2
CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2
CD22 expression	B Acute Lymphoblastic Leukemia	CD22 expression	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2
BCR-ABL1 E255K	Acute Lymphocytic Leukemia	BCR-ABL1 E255K	Acute Lymphocytic Leukemia	dasatinib + blinatumomab Sensitive: C3 – Early Trials dasatinib + blinatumomab Sensitive : C3	dasatinib + blinatumomab Sensitive: C3 – Early Trials dasatinib + blinatumomab Sensitive : C3
BCR-ABL1 D276G	Acute Lymphocytic Leukemia	BCR-ABL1 D276G	Acute Lymphocytic Leukemia	dasatinib + blinatumomab Sensitive: C3 – Early Trials dasatinib + blinatumomab Sensitive : C3	dasatinib + blinatumomab Sensitive: C3 – Early Trials dasatinib + blinatumomab Sensitive : C3
IL17A rs3819024	Acute Lymphocytic Leukemia	IL17A rs3819024	Acute Lymphocytic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
PAK4 deletion	B Acute Lymphoblastic Leukemia	PAK4 deletion	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
CDKN2A deletion	B Acute Lymphoblastic Leukemia	CDKN2A deletion	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	lenalidomide + tafasitamab-cxix Sensitive: C3 – Early Trials lenalidomide + tafasitamab-cxix Sensitive : C3	lenalidomide + tafasitamab-cxix Sensitive: C3 – Early Trials lenalidomide + tafasitamab-cxix Sensitive : C3
MLL rearrangement	Acute Lymphocytic Leukemia	MLL rearrangement	Acute Lymphocytic Leukemia	blinatumomab + inotuzumab ozogamicin Resistant: C3 – Early Trials blinatumomab + inotuzumab ozogamicin Resistant : C3	blinatumomab + inotuzumab ozogamicin Resistant: C3 – Early Trials blinatumomab + inotuzumab ozogamicin Resistant : C3
CDKN2A deletion	Acute Lymphocytic Leukemia	CDKN2A deletion	Acute Lymphocytic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	YT-19 Sensitive: C3 – Early Trials YT-19 Sensitive : C3	YT-19 Sensitive: C3 – Early Trials YT-19 Sensitive : C3
TP53 mutation	B Acute Lymphoblastic Leukemia	TP53 mutation	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
MLL rearrangement	B Acute Lymphoblastic Leukemia	MLL rearrangement	B Acute Lymphoblastic Leukemia	blinatumomab Resistant: C3 – Early Trials blinatumomab Resistant : C3	blinatumomab Resistant: C3 – Early Trials blinatumomab Resistant : C3
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	lenalidomide + tafasitamab-cxix Sensitive: C3 – Early Trials lenalidomide + tafasitamab-cxix Sensitive : C3	lenalidomide + tafasitamab-cxix Sensitive: C3 – Early Trials lenalidomide + tafasitamab-cxix Sensitive : C3
TP53 mutation	B Acute Lymphoblastic Leukemia	TP53 mutation	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Resistant: C3 – Early Trials blinatumomab + inotuzumab ozogamicin Resistant : C3	blinatumomab + inotuzumab ozogamicin Resistant: C3 – Early Trials blinatumomab + inotuzumab ozogamicin Resistant : C3
IKZF1 deletion	Acute Lymphocytic Leukemia	IKZF1 deletion	Acute Lymphocytic Leukemia	dasatinib + blinatumomab Resistant: C3 – Early Trials dasatinib + blinatumomab Resistant : C3	dasatinib + blinatumomab Resistant: C3 – Early Trials dasatinib + blinatumomab Resistant : C3
CD20 positive	B Acute Lymphoblastic Leukemia	CD20 positive	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
PD-1 overexpression	B Acute Lymphoblastic Leukemia	PD-1 overexpression	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
IKZF1 mutation	Acute Lymphocytic Leukemia	IKZF1 mutation	Acute Lymphocytic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
PAX5 mutation	Acute Lymphocytic Leukemia	PAX5 mutation	Acute Lymphocytic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
PAK4 deletion	Acute Lymphocytic Leukemia	PAK4 deletion	Acute Lymphocytic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3

CD19 inhibitor

CD19 inhibitor

Associations(61)

Associations
(61)